Oral RKS262 Reduces Tumor Burden in a Neuroblastoma (NB) Xenograft Animal Model and Mediates Cytotoxicity through SAPK/JNK and ROS Activation in Vitro
Singh R, Dorf L, DeMartino A, Illenye S, Koto K, Ashikaga T, Kwang Kim K, Brard L, Saulnier Sholler G. Oral RKS262 Reduces Tumor Burden in a Neuroblastoma (NB) Xenograft Animal Model and Mediates Cytotoxicity through SAPK/JNK and ROS Activation in Vitro. Cancer Biol Ther. 2011, 11:12, 1-10.









